TI
ENTA icon

Telemetry Investments’s Enanta Pharmaceuticals ENTA Stock Holding History

Telemetry Investments’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,200
Closed -$223K – 148
2017
Q2 		$223K Buy
+6,200
New +$198K 0.1% 96

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Telemetry Investments's ENTA Position: Q3 2017 in Review

Telemetry Investments sold out of Enanta Pharmaceuticals (ENTA) in Q3 2017, closing a stake of 6,200 shares — an estimated $223K sold.

Telemetry Investments first reported a position in ENTA in Q2 2017 and held it in 1 quarter. The position peaked at $223K in Q2 2017. 127 funds tracked by Wall St. Rank hold ENTA as of Q3 2017.

  • Telemetry Investments reported no remaining Enanta Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Telemetry Investments sold 6,200 Enanta Pharmaceuticals shares in Q3 2017, an estimated $223K.
  • Telemetry Investments first reported a position in Enanta Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Telemetry Investments's Enanta Pharmaceuticals position peaked at $223K in Q2 2017.
  • 127 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2017.

Based on Telemetry Investments's 13F filing for Q3 2017, filed 14 Nov 2017.